• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Virpax Pharmaceuticals Inc.

    5/23/24 4:06:37 PM ET
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VRPX alert in real time by email
    SC 13G 1 ea0206681-13gintra_virp.htm SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    Virpax Pharmaceuticals, Inc.

     

    (Name of Issuer)

     

    Common stock, par value $0.00001 per share

     

    (Title of Class of Securities)

     

    928251206

    (CUSIP Number)

     

    May 14, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a. ☐ Rule 13d-1(b)
    b. ☒ Rule 13d-1(c)
    c.   ☐ Rule 13d-1(d)

      

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 928251206

     

         
    1. Names of Reporting Persons.
       
      Mitchell P. Kopin
       
       
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
         
      (a)  ☐  
      (b)  ☐  
         
         
    3. SEC Use Only
         
         
    4. Citizenship or Place of Organization United States of America
         

     

    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
    5.  Sole Voting Power 0
       
       
    6.  Shared Voting Power 110,727
       
       
    7.  Sole Dispositive Power 0
       
       
    8.  Shared Dispositive Power 110,727
         
         
    9. Aggregate Amount Beneficially Owned by Each Reporting Person 110,727 (see Item 4)
         
         
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
         
         
    11. Percent of Class Represented by Amount in Row (9) 4.99% (see Item 4)
         
         
    12. Type of Reporting Person (See Instructions)
       
      IN; HC
       

     

    Page 2 of 8

     

     

    CUSIP No. 928251206

     

         
    1. Names of Reporting Persons.
       
      Daniel B. Asher
       
       
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
         
      (a)  ☐  
      (b)  ☐  
         
         
    3. SEC Use Only
         
         
    4. Citizenship or Place of Organization United States of America
         

     

    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
    5.  Sole Voting Power 0
       
       
    6.  Shared Voting Power 110,727
       
       
    7.  Sole Dispositive Power 0
       
       
    8.  Shared Dispositive Power

    110,727

         
         
    9. Aggregate Amount Beneficially Owned by Each Reporting Person 110,727 (see Item 4)
         
         
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
         
         
    11. Percent of Class Represented by Amount in Row (9) 4.99% (see Item 4)
         
         
    12. Type of Reporting Person (See Instructions)
       
      IN; HC
       

     

    Page 3 of 8

     

     

    CUSIP No. 928251206

     

         
    1. Names of Reporting Persons.
       
      Intracoastal Capital LLC
       
       
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
         
      (a)  ☐  
      (b)  ☐  
         
         
    3. SEC Use Only
         
         
    4. Citizenship or Place of Organization Delaware
         

     

    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
    5.  Sole Voting Power 0
       
       
    6.  Shared Voting Power 110,727
       
       
    7.  Sole Dispositive Power 0
       
       
    8.  Shared Dispositive Power 110,727
         
         
    9. Aggregate Amount Beneficially Owned by Each Reporting Person 110,727 (see Item 4)
         
         
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
         
         
    11. Percent of Class Represented by Amount in Row (9) 4.99% (see Item 4)
         
         
    12. Type of Reporting Person (See Instructions)
       
      OO
       

     

    Page 4 of 8

     

     

    Item 1.

     

    (a) Name of Issuer

     

    Virpax Pharmaceuticals, Inc. (the “Issuer”)

     

    (b) Address of Issuer’s Principal Executive Offices

     

    1055 Westlakes Drive, Suite 300

    Berwyn, Pennsylvania 19312

     

    Item 2.

     

    (a) Name of Person Filing

    (b) Address of Principal Business Office or, if none, Residence

    (c) Citizenship

     

    This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America (“Mr. Kopin”), (ii) Daniel B. Asher, an individual who is a citizen of the United States of America (“Mr. Asher”) and (iii) Intracoastal Capital LLC, a Delaware limited liability company (“Intracoastal” and together with Mr. Kopin and Mr. Asher, collectively the “Reporting Persons”).

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

     

    The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483.

     

    The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.

     

    (d) Title of Class of Securities

     

    Common stock, par value $0.00001 per share, of the Issuer (the “Common Stock”).

     

    (e) CUSIP Number

     

    928251206

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Page 5 of 8

     

     

    Item 4. Ownership.

     

    (a) and (b):

     

    (i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on May 14, 2024 (the “SPA”) (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on May 17, 2024), each of the Reporting Persons may have been deemed to have beneficial ownership of 110,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA, and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 8.6% of the Common Stock, based on (1) 1,171,233 shares of Common Stock outstanding as of May 14, 2024 as reported by the Issuer, plus (2) 110,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA. The foregoing excludes (I) 110,000 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (“Intracoastal Warrant 1”) because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock and (II) 110,000 shares of Common Stock issuable upon exercise of a second warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (“Intracoastal Warrant 2”) because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 330,000 shares of Common Stock.

     

    (ii) As of the close of business on May 23, 2024, each of the Reporting Persons may have been deemed to have beneficial ownership of 110,727 shares of Common Stock, which consisted of (i) 110,000 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 and (ii) 727 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 4.99% of the Common Stock, based on (1) 1,171,233 shares of Common Stock outstanding as of May 14, 2024 as reported by the Issuer, plus (2) 937,034 shares of Common Stock issued at the closing of the transaction contemplated by the SPA, (3) 110,000 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 and (4) 727 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2. The foregoing excludes 109,273 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provision, each of the Reporting Persons may have been deemed to have beneficial ownership of 220,000 shares of Common Stock.

     

    (c) Number of shares as to which each Reporting Person has:

     

    (i) Sole power to vote or to direct the vote:    0   .

     

    (ii) Shared power to vote or to direct the vote:      110,727      .

     

    (iii) Sole power to dispose or to direct the disposition of      0     .

     

    (iv) Shared power to dispose or to direct the disposition of      110,727     .

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Page 6 of 8

     

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 7 of 8

     

      

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: May 23, 2024

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
       
      /s/ Daniel B. Asher
      Daniel B. Asher
       
      Intracoastal Capital LLC
         
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

    Page 8 of 8

    Get the next $VRPX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VRPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VRPX
    Financials

    Live finance-specific insights

    See more
    • Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments

      Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended March 31, 2024, and other recent developments. "We recently reported results for a Probudur™ Maximum Tolerated Dose Study, as we continue to make steady progress in anticipation of filing our IND. The results of this study, as expected, confirmed our belief that a single injection of Probudur was well-tolerated. Our studies to date continue to reaffirm our belief that Probu

      5/13/24 4:10:00 PM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virpax Pharmaceuticals Reports 2023 Year-End Results

      Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the twelve months ended December 31, 2023, and other recent developments. "We are off to a strong start in 2024 and are pleased to have regained compliance with Nasdaq. Additionally, we have executed a settlement agreement with the Plaintiffs, and can now focus on developing our non-addictive product candidates for pain management," commented Gerald W. Bruce, Chief Executive Officer of Virpax.

      3/26/24 7:30:00 AM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments

      Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended September 30, 2023, and other recent developments. "We recently announced results from two preclinical studies for Probudur™, our lead product candidate for post operative pain, that demonstrated significantly longer efficacy in animal models than the product currently on the market today. With these solid results, we believe we are on track to file our Investigational New

      11/15/23 4:15:00 PM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRPX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Virpax Pharmaceuticals Announces Reverse Stock Split

      Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company") a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split ("reverse split") of its common stock, par value $0.0001 per share ("Common Stock"), that will become effective at 12:01 a.m. Eastern Time on March 20, 2025. The Company's Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "VRPX" and will begin trading on a split-adjusted basis when the Nasdaq opens on March 21, 2025 ("Effective

      3/19/25 8:00:00 AM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND

      Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced positive results from a beagle dog dose range finding ("DRF") study. Probudur is the company's long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate and extended pain relief. The Company continues to work towards its Investigational New Drug (IND) application and this was another important step towards that milestone. The DRF study was conducted to evaluate the tolerance of Pr

      3/18/25 4:01:00 PM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virpax Looking to Use MET to Develop Intranasal COVID Vaccine

      Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is looking to use Molecular Envelope Technology (MET) or a similar technology to deliver a mRNA COVID vaccine. Virpax currently uses its MET for Envelta (NES100) and NobrXiol (VRP324). The Company will look to explore delivery of vaccines via intranasal delivery similar to the FluMist which is used for patients with a fear of needles. The current vaccines in the market use lipid delivery technology to deliver mRNA to induce an immune

      3/7/25 8:00:00 AM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRPX
    SEC Filings

    See more
    • Amendment: Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits

      8-K/A - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)

      4/3/25 5:00:46 PM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virpax Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits

      8-K - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)

      4/3/25 11:00:41 AM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form S-1/A filed by Virpax Pharmaceuticals Inc.

      S-1/A - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)

      3/25/25 6:10:49 AM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Panis Jaydriane

      3 - Virpax Pharmaceuticals, Inc. (0001708331) (Issuer)

      1/8/25 4:11:17 PM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Chaudhry Usama

      3 - Virpax Pharmaceuticals, Inc. (0001708331) (Issuer)

      1/6/25 4:05:29 PM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Randhawa Esha

      3 - Virpax Pharmaceuticals, Inc. (0001708331) (Issuer)

      12/4/24 8:30:14 PM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $VRPX
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form SC 13G filed by Virpax Pharmaceuticals Inc.

      SC 13G - Virpax Pharmaceuticals, Inc. (0001708331) (Subject)

      5/23/24 4:06:37 PM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Virpax Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Virpax Pharmaceuticals, Inc. (0001708331) (Subject)

      1/2/24 10:11:28 AM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Virpax Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Virpax Pharmaceuticals, Inc. (0001708331) (Subject)

      2/14/23 4:05:43 PM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

      GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Vinay Shah as the Company's Chief Financial Officer, effective November 16, 2024. Vinay Shah is an accomplished Chief Financial Officer with over 25 years of experience in the pharmaceutical, biopharmaceutical, and healthcare sectors, specializing in financial strategy, investor relations, and operational efficiency. Most recently, Mr. Shah served as the CFO at Virpax Pharmaceuticals, Inc. (N

      11/5/24 8:30:00 AM ET
      $ADIL
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virpax Pharmaceuticals Announces Leadership Transition

      Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that due to ongoing litigation it has accepted the resignation of Anthony P. Mack as CEO and Chairman effective immediately. The Board has appointed Gerald Bruce as CEO and Dr. Eric Floyd as Chairman. Mr. Bruce has served as the Company's Executive Vice President of Commercial Operations since August 2017, as a member of the Company's Board since July 2021 and as the President and CEO of the Company's wholly owned su

      11/17/23 7:00:00 AM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors

      Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, announced today that the Company has appointed Barbara A. Ruskin, Ph.D, J.D. to its Board of Directors, increasing the size of the Board to nine members. Dr. Ruskin, who received her Ph.D. in Biochemistry & Molecular Biology from Harvard University, is an experienced attorney specializing in life sciences and intellectual property. Most recently she serves as the Chief Intellectual Property and Innovation Officer for Silence Therapeutics,

      3/28/23 8:58:00 AM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care